S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NASDAQ:BPTH

Bio-Path - BPTH Stock Forecast, Price & News

$1.47
0.00 (0.00%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.45
▼
$1.56
50-Day Range
$1.34
▼
$3.46
52-Week Range
$1.28
▼
$4.80
Volume
40,890 shs
Average Volume
48,668 shs
Market Capitalization
$10.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Bio-Path MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
512.2% Upside
$9.00 Price Target
Short Interest
Healthy
0.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.09mentions of Bio-Path in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.85) to ($1.68) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

330th out of 1,022 stocks

Pharmaceutical Preparations Industry

135th out of 499 stocks

See Top Rated MarketRank™ Stocks Here
BPTH stock logo

About Bio-Path (NASDAQ:BPTH) Stock

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Stock News Headlines

December 9, 2022 | americanbankingnews.com
Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com
December 7, 2022 | finance.yahoo.com
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
December 1, 2022 | americanbankingnews.com
Bio-Path (NASDAQ:BPTH) Receives New Coverage from Analysts at StockNews.com
November 15, 2022 | finance.yahoo.com
Bio-Path Holdings Reports Third Quarter 2022 Financial Results
November 8, 2022 | finance.yahoo.com
Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022
November 7, 2022 | finance.yahoo.com
Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement
October 24, 2022 | finance.yahoo.com
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
October 19, 2022 | bizjournals.com
Arrivo BioVentures advances depression treatment with focus on women - The Business Journals
October 18, 2022 | seekingalpha.com
Organogenesis Stock: Finding A Spot In My Bio Boom Portfolio - Seeking Alpha
October 13, 2022 | businesswire.com
Therapeutic Drug Monitoring Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update - ResearchAndMarkets.com - Business Wire
October 12, 2022 | nasdaq.com
Eni (E) Begins Vegetable Oil Export From Kenya's Agri-hub - Nasdaq
October 10, 2022 | businesswire.com
Global Incontinence Devices Pipeline Research Report 2022: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies - ResearchAndMarkets.com - businesswire.com
October 7, 2022 | streetinsider.com
Entera Bio (ENTX) Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 - StreetInsider.com
October 3, 2022 | benzinga.com
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future - blueb - Benzinga
September 30, 2022 | benzinga.com
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) - Bio-Path Holdings (NASDAQ - Benzinga
September 29, 2022 | finance.yahoo.com
The Engine Opens New Headquarters in Cambridge: 155,000 Square Foot Building with Bio and Chem Labs, Industrial Workshops, and Office and Event Space Will Bring Together the Tough Tech Ecosystem - Yahoo Finance
September 27, 2022 | businesswire.com
Colossal Biosciences Spins Out Form Bio to Revolutionize Computational Life Sciences - Business Wire
September 16, 2022 | benzinga.com
J INTS BIO's Novel Oral 4th Generation EGFR-TKI 'JIN-A02' effective against both cis and trans isomers of C797S mutations - ESMO 2022 - Benzinga
September 16, 2022 | benzinga.com
Palisade Bio (NASDAQ:PALI) – Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to F - Benzinga
September 15, 2022 | benzinga.com
Contract Injectable Packaging Trends in the Bio/Pharma Industry - Benzinga
September 12, 2022 | benzinga.com
Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines - Benzinga
September 10, 2022 | finance.yahoo.com
Indonesian Pharmaceutical PT Bio Farma Ready to Mass Produce IndoVac Covid-19 Vaccines - Yahoo Finance
September 9, 2022 | businesswire.com
Global Cardiac Markers Rapid Tests and POC Pipeline Report 2022 - Featuring 1Drop Diagnostics, Abbott Point of Care and Accel Diagnostics Among Others - ResearchAndMarkets.com - Business Wire
September 9, 2022 | benzinga.com
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines - Benzinga
September 8, 2022 | finance.yahoo.com
Chardan Announces the Inaugural SPICI (Smart People in Cellular Immunotherapy) Symposium - Yahoo Finance
See More Headlines
Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Company Calendar

Last Earnings
11/12/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/10/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPTH
CUSIP
N/A
CIK
1133818
Web
www.biopathholdings.com
Phone
(832) 742-1357
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+512.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,440,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-67.16%
Return on Assets
-62.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.24
Quick Ratio
8.24

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.56 per share
Price / Book
0.41

Miscellaneous

Outstanding Shares
7,160,000
Free Float
6,907,000
Market Cap
$10.53 million
Optionable
Not Optionable
Beta
1.26

Key Executives

  • Mr. Peter H. Nielsen MBA (Age 73)
    Co-Founder, Chairman, CEO, Pres, CFO & Treasurer
    Comp: $680.18k
  • Mr. Douglas P. Morris (Age 66)
    Co-Founder, Director of Investor Relations, Sec. & Director
    Comp: $68.47k
  • Mr. Anthony Price
    Sr. VP of Fin., Accounting & Admin.
  • Dr. Ana Tari Ashizawa Ph.D.
    MBA, Sr. VP of Research, Devel. & Clinical Design
  • Dr. Alan MacKenzie Ph.D.
    Consultant
  • Dr. Thomas A. Walker Ph.D.
    Consultant
  • Dr. Jeffery Lancet M.D.
    Consultant
  • Ms. Victoria Lake Rac
    Regulatory Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BPTH Stock - Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPTH shares.
View BPTH analyst ratings or view top-rated stocks.

What is Bio-Path's stock price forecast for 2023?

1 brokers have issued 12 month price objectives for Bio-Path's stock. Their BPTH share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 512.2% from the stock's current price.
View analysts price targets for BPTH or view top-rated stocks among Wall Street analysts.

How have BPTH shares performed in 2022?

Bio-Path's stock was trading at $3.77 on January 1st, 2022. Since then, BPTH stock has decreased by 61.0% and is now trading at $1.47.
View the best growth stocks for 2022 here.

When is Bio-Path's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 10th 2023.
View our BPTH earnings forecast.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. During the same quarter in the prior year, the company earned ($0.80) earnings per share.

When did Bio-Path's stock split?

Shares of Bio-Path reverse split on the morning of Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by a variety of institutional and retail investors. Top institutional investors include Mount Yale Investment Advisors LLC (0.35%), Virtu Financial LLC (0.17%) and Citadel Advisors LLC (0.15%).
View institutional ownership trends.

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $1.47.

How much money does Bio-Path make?

Bio-Path (NASDAQ:BPTH) has a market capitalization of $10.53 million. The company earns $-10,440,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The official website for the company is www.biopathholdings.com. The company can be reached via phone at (832) 742-1357 or via email at will@sternir.com.

This page (NASDAQ:BPTH) was last updated on 12/9/2022 by MarketBeat.com Staff